Top Story

FDA grants breakthrough therapy designation to ACE910 for hemophilia A

September 4, 2015

The FDA granted breakthrough therapy designation to ACE910 for the prophylactic treatment of patients aged at least 12 years who have hemophilia A with factor VIII inhibitors, according to a press release from the drug’s manufacturer.

The FDA based its decision in part on results of a phase 1 trial presented at the 2014 ASH Annual Meeting and Exposition and the subsequent phase 1/2 extension study presented at the International Society of Thrombosis and Haemostasis 2015 Congress.

In the JournalsPerspective

Advanced care planning rates increase modestly among patients with cancer

September 4, 2015
The use of advanced care planning among patients with cancer increased modestly between 2000 and 2012, according to an analysis of prospectively collected survey data.A…

New ACA rule aims to protect patients from sex, disability discrimination

September 4, 2015
The HHS has announced a proposed rule to modify discrimination provisions of the Affordable Care Act, which would help provide equal access to health care and coverage…
Robert L. Coleman, MD In the Journals

Bisphosphonates improve breast cancer survival in postmenopausal women

September 4, 2015
Adjuvant treatment with bisphosphonates reduced the rate of breast cancer recurrence in the bone and improved breast-cancer survival among women who were postmenopausal…
In the Journals

Extent of lymphadenectomy may not influence survival in esophageal cancer

September 3, 2015
The number of lymph nodes removed during lymphadenectomy may not influence 5-year all-cause or disease-specific survival among patients with esophageal cancer, according…
More News Headlines »
Hematology Oncology Case Consults

The Patient with Pancreatic Cancer

No commercial support for this activity.

Pancreatic cancer only accounts for 3% of cancer cases, but it is the fourth leading cause of cancer-related death…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »